2X1:ETR
Abivax SA
€78.45
0.00%
(0.00) 1 天
10月12日, GMT+2 17:35:43 · EUR
search
所有股票代码
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 2X1 生成关键数据洞见…
市值
69.41亿
平均成交量
1787.00
成交量
0.00
52 周最高价
€137.40
52 周最低价
€60.85
每股收益
-€5.20
员工人数
98
市值
69.41亿
平均成交量
1787.00
成交量
0.00
52 周最高价
€137.40
52 周最低价
€60.85
每股收益
-€5.20
员工人数
98
新闻报道
来自网络来源和新闻合作伙伴
https://www.dars.gov.et/
·
3天前
ABVX Q2 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Keeps Spending on Pipeline
资料
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Abivax SA简介